Costello Asset Management INC Has $4.41 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Costello Asset Management INC reduced its stake in Boston Scientific Corporation by 33.1% during the second quarter, now holding 41,063 shares valued at approximately $4.41 million.
• Boston Scientific's recent earnings report showed a 22.8% revenue increase year-over-year, with EPS at $0.75, exceeding the consensus estimate by $0.03.
• Insider selling saw a significant turnover, with insiders offloading 174,214 shares valued at nearly $18 million over the last quarter.

Costello Asset Management INC trimmed its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 33.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,063 shares of the medical equipment provider's stock after selling 20,288 shares during the quarter. Boston Scientific comprises approximately 1.7% of Costello Asset Management INC's holdings, making the stock its 15th largest position. Costello Asset Management INC's holdings in Boston Scientific were worth $4,411,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter worth $27,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after buying an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management lifted its stake in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after buying an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.5%

Shares of Boston Scientific stock opened at $97.28 on Friday. The firm has a market capitalization of $144.14 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company's fifty day moving average price is $102.18 and its two-hundred day moving average price is $101.92. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BSX. BTIG Research boosted their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. UBS Group boosted their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $121.00 target price on shares of Boston Scientific in a research report on Wednesday, October 1st. Evercore ISI dropped their target price on shares of Boston Scientific from $115.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and an average target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.